Improving automated prostate cancer risk assessment: An ensemble LLM framework for clinical T-stage inference and NCCN risk stratification.

U Umair Ayub (1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States) S Syed Arsalan Ahmed Naqvi (Mayo Clinic, Phoenix, AZ) M Muhammad Umar Afzal (Mayo Clinic Arizona, Scottsdale, AZ) S Salman Ayub Jajja (NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States) J Ji-Eun Irene Yum (Mayo Clinic Alix School of Medicine, Phoenix, AZ) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) P Parminder Singh (Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ) I Irbaz Bin Riaz (Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA)

Abstract

e17005 Background: We previously developed a hybrid framework combining LLMs and rule-based algorithms (RBA) for automated risk stratification in localized prostate cancer (locPCa), achieving 89% accuracy. However, clinical T-stage (cTS) inference from narrative MRI reports remained the primary source of errors. Herein, we evaluated whether ensemble approaches using multiple state-of-the-art LLMs could improve cTS inference and overall NCCN risk stratification accuracy. Methods: This study included patients with locPCa presenting with at least one positive prostate biopsy and MRI report available. Building on our previously validated hybrid framework that extracts structured phenotypic variables (PSA, prostate volume, cTS, Gleason patterns, grade group, positive and examined cores) from unstructured reports using LLMs and applies NCCN-concordant RBA for risk stratification, we focused on improving cTS inference. Four HIPAA-compliant LLMs (GPT-4.1, GPT-5.1, Gemini-2.5-Pro, Gemini-2.5-Flash) were evaluated using structured zero-shot prompts iteratively refined through oncologist feedback. Majority voting was employed to generate consensus cTS predictions. Performance was evaluated using weighted accuracy. Results: A total of 358 patients were included. The median age at diagnosis was 65 years (IQR: 60-69); the majority were White (92%) and non-Hispanic (94%). cTS distribution was T2a (51%), T2c (20%), T3a (16%), T3b (7%), T2b (4%), and T4 (2%). The most prevalent risk category was unfavorable intermediate (38%) followed by favorable intermediate (20%), high risk (19%), very high risk (16%), low (5%), and very low (1%). Individual LLM accuracy for cTS inference ranged from 85-90%, with Gemini-2.5-Pro achieving highest accuracy (90%), followed by GPT-4.1 (88%), GPT-5.1 (87%), and Gemini-2.5-Flash (85%). The four-model ensemble reached consensus in 92% of cases, achieving 93% cTS inference accuracy. When integrated into NCCN risk stratification schema, single-model approaches achieved 89-92% accuracy, while ensemble consensus cases achieved 95% accuracy. Conclusions: The ensemble framework using multiple LLMs significantly improves cTS inference and achieves 95% NCCN risk stratification accuracy in consensus cases (92% of patients), representing a 6-percentage-point improvement over our previous single-model framework (89%). This strategy demonstrates that ensemble methods can overcome individual model limitations for complex clinical tasks and holds promise for reliable AI-assisted risk stratification.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

U

Umair Ayub

1Mayo Clinic, Division of Hematology/Oncology, Department of Internal Medicine, Phoenix, United States

S

Syed Arsalan Ahmed Naqvi

Mayo Clinic, Phoenix, AZ

M

Muhammad Umar Afzal

Mayo Clinic Arizona, Scottsdale, AZ

S

Salman Ayub Jajja

NYMC-LANDMARK MEDICAL CENTER, RI, Woonsocket, Rhode Island, United States

J

Ji-Eun Irene Yum

Mayo Clinic Alix School of Medicine, Phoenix, AZ

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

P

Parminder Singh

Department of Medicine, Mayo Clinic Alix School of Medicine, Phoenix, AZ

I

Irbaz Bin Riaz

Irbaz Bin Riaz, MD, PhD; R. Bryan Rumble, MSc; Thomas A. Hope, MD; Giuseppe Procopio, MD; and Neha Vapiwala, MD; Mayo Clinic, Phoenix, AZ; American Society of Clinical Oncology, Alexandria, VA; University of California, San Francisco, San Francisco, CA; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy; and University of Pennsylvania Abramson Cancer Center, Philadelphia, PA